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BACKGROUND. Craniofacial osteosarcoma differs from long bone osteosarcoma in
that patients are older, tumors are often low grade, and prognosis is more favor-
able. Although most are sporadic, some tumors occur in association with prior
radiation therapy. The purpose of the current study was to compare clinicopatho-
logic and prognostic features of primary and radiation-associated osteosarcoma.
METHODS. The study group consisted of 15 primary and 6 radiation-associated
osteosarcomas. Clinical and follow-up data were obtained in every case. Tissue
microarrays were immunohistochemically stained for p53, pRB, Ki-67 (MIB-1),
and ezrin. DNA was sequenced for TP53 mutations.
RESULTS. All radiation-associated osteosarcomas were high grade and half were
fibroblastic. In contrast, 47% of primary craniofacial osteosarcomas were high
grade and only 1 was fibroblastic. All radiation-associated osteosarcomas re-
curred, half the patients died of disease, 2 were alive with unresectable tumors,
whereas only 1 was alive without disease. In contrast, 80% of patients with pri-
mary tumors were alive without disease, 33% had local recurrences, and 13%
died of disease. Radiation-associated tumors overexpressed p53 more often (33%
vs. 13%), more often had TP53 mutations (33% vs. 8%), had higher proliferative
activity (67% vs. 0% showing >50% MIB-1 staining), and expressed ezrin more
frequently (83% vs. 40%) than primary tumors. Compared with a control group of
24 high- and 7 low-grade primary extremity osteosarcomas, radiation-associated
tumors marked as the high-grade tumors.
CONCLUSIONS. Craniofacial radiation-associated osteosarcomas are high-grade
tumors that behave more aggressively than most primary craniofacial osteosarco-
mas. In addition, they demonstrate higher expression rates of adverse prognostic
indicators, further highlighting the distinction. Cancer 2006;107:554–62.
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C raniofacial osteosarcoma accounts for 6% to 10% of all osteosar-comas and usually occurs in the mandible or maxilla.1–3
Patients tend to be older than those with osteosarcoma of the long
bones, with a peak incidence in the fourth decade.4 These osteosar-
comas are more frequently low grade and half are chondroblas-
tic.2,4–6 Osteoblastic osteosarcoma is also common in this
location, but fibroblastic osteosarcoma uncommon.7
The prognosis is more favorable compared with conventional
osteosarcoma of the extremities and the mainstay of therapy is sur-
gical resection.8 Morbidity and mortality are primarily due to local
recurrence, hence prognosis is largely dependent on margin status
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at resection.9 Distant metastases are uncommon.8
Unlike its counterpart in the long bones, the role of
chemotherapy in the treatment of craniofacial osteo-
sarcoma remains to be proven.3
Most cases of craniofacial osteosarcoma are
sporadic.2 However, known predisposing factors
include fibrous dysplasia, Paget disease, retinoblas-
toma, Li-Fraumeni syndrome, and previous radiation
therapy.10 Secondary osteosarcomas of the head and
neck are uncommon and, accordingly, radiation-as-
sociated craniofacial osteosarcoma is rare. Osteosar-
coma is a common phenotype of radiation-associated
sarcoma, accounting for half the cases,11 with ap-
proximately 10% occurring in the head and neck region.9
The latent period after radiation averages 11 years
(range, 4–23 years) in the head and neck,9 and its
length is inversely proportional to radiation dosage.13
Compared with primary craniofacial osteosar-
coma, craniofacial radiation-associated osteosarcoma
tends to be higher grade,8,14,15 more often fibroblas-
tic,10,14 shows higher levels of p53 expression,2 and
has a less favorable prognosis.9,12,14 In contrast to
conventional osteosarcoma and similar to primary
craniofacial osteosarcoma, radiation-associated cra-
niofacial osteosarcomas has been found to demon-
strate a low incidence of metastases.3,4 A significant
factor impacting survival is locally aggressive growth.9
However, reports of craniofacial radiation-associated
osteosarcoma are limited and not all studies were
able to demonstrate behavioral differences with pri-
mary craniofacial osteosarcoma.16–18
The purpose of this study was to better under-
stand biologic and clinicopathologic differences
between primary and radiation-associated craniofa-
cial osteosarcoma. We analyzed a series of 21 cases,
comparing patient characteristics and outcomes, his-
topathology, and immunohistochemical and molecu-
lar data on a number of prognostic indicators. In
addition, we compared the prognostic markers in 31
extremity osteosarcomas, both high- and low-grade
tumors, as a control group.
MATERIALS AND METHODS
Twenty-one patients with craniofacial osteosarcoma
were identified from the files of the Department of
Pathology at the University of Michigan (15 cases)
and Wayne State University (6 cases) between 1986–
2004. Clinical and follow-up data were obtained from
medical records, referring clinicians, and the Social
Security death registry.
All sections from each case were reviewed by 2
pathologists (J.B.M. and D.R.L.) to confirm the diag-
nosis and to determine subclassification and grade.
Tumors were subclassified as osteoblastic, chondro-
blastic or fibroblastic according to the predominant
histologic element, and were graded using a 2-tiered
system of low and high grade. After pathologic
review, a tissue microarray (TMA) was constructed
from the most representative areas using the metho-
dology of Nocito et al.19 Representative sections from
24 high-grade and 7 low-grade extremity osteosarco-
mas were used as a comparative control group.
Immunohistochemistry
Immunohistochemical staining was performed on a
DAKO Autostainer (DAKO, Carpinteria, CA) using
DAKO LSABþ and diaminobenzadine as the chromo-
gen. Deparaffinized sections of the TMA at 5-m thick-
ness were labeled with antibodies to p53 (rabbit
polyclonal antibody, 1:100, NCL-p53-CM1 Novocas-
tra, Newcastle, UK), retinoblastoma protein (pRB)
(mouse monoclonal antibody, 1:50, NCL-RB-358,
Novocastra), ezrin (mouse monoclonal antibody, 1:200,
3C12, Zymed, San Francisco, CA), or Ki-67 (mouse
monoclonal antibody, 1:100, MIB-1, DAKO). p53,
pRB, and ezrin immunohistochemistry required micro-
wave citric acid epitope retrieval. Staining with Ki-67
required microwave antigen retrieval in high pH buf-
fer. Appropriate negative (no primary antibody) and
positive controls were stained in parallel with each
set of tumors studied.
TMA cores stained with anti-p53 and anti-pRB
antibodies were scored as positive if strong nuclear
staining was identified in >50% of cells for p53 and
in any positive cells for pRB. TMA cores stained with
anti-ezrin antibody were scored as positive when
cytoplasmic and/or membranous staining was pre-
sent. TMA cores stained with anti-Ki-67 antibody
were scored as <10, 10–25, 25–50, or >50% based
on the percentage of cells demonstrating nuclear
staining.
Sequence Analysis of p53
DNA was extracted from 3 5-mm thick sections of
each tissue block using a Nucleon HT DNA extrac-
tion kit (Amersham Biosciences, Piscataway, NJ)
according to the manufacturer’s instructions. Geno-
mic exons 5, 6, 7, and 8 of the p53 gene were sepa-
rately amplified according to the methods of de Vos
et al.20 Amplified product was purified using a
Wizard SV PCR clean-up kit (Promega, Madison, WI)
and sequenced directly within the University of
Michigan Medical Center DNA Sequencing Core
using an ABI 377 DNA sequencer (ABI, Foster City,
CA). Chromatograms were downloaded directly to
CodonCode Aligner software (v. 1.3.4, Dedham, MA)
and the sequence compared with reference sequence
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downloaded from the National Center of Biotechnol-
ogy Information (NCBI; p53 reference sequence
number: NM_000546, http://www.ncbi.nlm.nih.gov
[Accessed February 27, 2006]).
RESULTS
Patient Characteristics (Table 1)
The median age at diagnosis was 37 years (range, 16–
73 years). Patients with radiation-associated osteosar-
coma had a higher median age at diagnosis than those
with primary osteosarcoma (43 vs. 33 years). Half the
patients were men, including 5 of 6 with radiation-
associated and 6 of 15 with primary osteosarcoma.
The mandible and maxilla were equally involved (10
cases for each site) and 1 patient had an oropharyn-
geal osteosarcoma.
Six (29%) patients had a history of radiation in
the field where the osteosarcoma arose. The median
latency period was 18 years (range, 9–24 years). In 1
patient the interval was unknown. Two patients had
radiation for squamous cell carcinoma, 1 involving
the oral mucosa (Patient 16) and the other involving
the larynx (Patient 17). Two patients received radia-
tion for retinoblastoma (Patients 18 and 19), 1 for
Ewing sarcoma (Patient 20), and 1 for parotid adeno-
carcinoma (Patient 21).
Pathology
All tumors demonstrated classic light microscopic
features of osteosarcoma. Evidence of malignant
osteoid production, albeit focal in some, was present
in every case. Of the primary osteosarcomas, 9 (60%)
were osteoblastic (Fig. 1) and 5 (33%) were chondro-
blastic (Fig. 2). Only 1 primary osteosarcoma was
fibroblastic. In contrast, half the radiation-associated
osteosarcomas were fibroblastic (Fig. 3), whereas 3
were osteoblastic and none chondroblastic. All radia-
tion-associated osteosarcomas were high grade com-
pared with only 7 (47%) of the primary osteosarcomas.
Immunohistochemistry and TP53 Mutational
Analysis (Table 2)
More radiation-associated osteosarcomas overexpressed
p53 protein than primary osteosarcomas, with 33%
compared with 13% having strong nuclear staining
in >50% of the cells (Fig. 4). Mutation of the TP53
gene was also more common in radiation-associated
osteosarcoma. Two (33.3%) radiation-associated osteo-
sarcomas had TP53 mutations (one involving exon 7
at codon 175 and 1 involving exon 5 at codon 248),
TABLE 1




years Site Histologic type Grade Recurrence Metastasis Follow-up, months
1 22/F No Mandible Osteoblastic Low No No NED/36
2 29/F No Mandible Osteoblastic Low No No NED/41
3 16/F No Mandible Chondroblastic Low No No NED/108
4 13/F No Maxilla Osteoblastic Low Yes No NED/96
5 37/F No Mandible Osteoblastic Low No No NED/12
6 37/M No Maxilla Chondroblastic Low No No NED/156
7 62/F No Maxilla Chondroblastic Low No No NED/24
8 48/F No Maxilla Osteoblastic Low No No NED/216
9 12/M No Mandible Osteoblastic High No No NED/14
10 64/M No Maxilla Osteoblastic High No No NED/168
11 30/M No Maxilla Chondroblastic High Yes No DOD/24
12 19/F No Mandible Chondroblastic High No No NED/51
13 20/M No Mandible Fibroblastic High Yes Lymph node NED/38
14 29/M No Mandible Osteoblastic High Yes No AWD/14
15 64/F No Maxilla Osteoblastic High Yes No DOD/15
16 53/M Yes/? Mandible Osteoblastic High Yes Unknown DOD/21
17 71/M Yes/9 Oropharynx Osteoblastic High Yes No AWD/12
18 26/M Yes/22 Maxilla Osteoblastic High Yes Brain DOD/24
19 19/M Yes/18 Maxilla Fibroblastic High Yes No AWD/84
20 33/F Yes/18 Maxilla Fibroblastic High Yes No NED/48
21 73/M Yes/24 Mandible Fibroblastic High Yes No DOD/19
NED indicates no evidence of disease; AWD, alive with disease; DOD, died of disease.
Boldfaced type (16–21) designates radiation-associated.
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whereas only 1 primary osteosarcoma (8%) had a
TP53 mutation (involving exon 7 at codon 248). In 3
primary osteosarcomas we were unable to amplify
DNA due to technical restraints and these cases were
excluded from mutational analysis.
Expression of pRB was similar in both groups,
with nuclear staining identified in 50% of the radia-
tion-associated and 53% of the primary osteosarco-
mas. Immunoreactivity for the membrane cytoskeletal
organizer protein ezrin was higher in radiation-asso-
ciated osteosarcoma, identified in 5 of 6 (83%) com-
pared with only 6 of 15 (40%) of the primary
osteosarcomas (Fig. 5). Ezrin expression was inde-
pendent of grade among the primaryprintaslevel cra-
niofacial osteosarcoma group, with 4 of 6 (67%) low-
grade tumors being positive compared with 2 of 9
(22%) high-grade tumors. Proliferative activity was
higher in radiation-associated osteosarcoma, with 4 of
6 (67%) showing >50% Ki-67 nuclear staining com-
pared with none with >50% staining in primary
osteosarcoma.
In a control group of 31 extremity osteosarcomas
(Table 3), the high-grade tumors (n ¼ 24) had a
higher rate of p53 expression (18% vs. 0%), higher
rate of TP53 mutation (21% vs. 14%), more ezrin-
positivity (72% vs. 57%), and greater proliferative
activity (50% with Ki-67 staining in >50% of cells vs.
0%) compared with the low-grade tumors (n ¼ 7).
The TP53 mutation incidences reported herein are
consistent with those reported elsewhere for high-21
and low-grade osteosarcomas.22
Follow-up (Table 1)
Follow-up information was available for all patients,
with a mean follow-up time of 57 months (range, 12–
216 months). Chemotherapy with or without radia-
tion was given to 67% of primary craniofacial osteo-
sarcoma patients compared with 80% of radiation-
associated osteosarcoma patients. All six patients
with radiation-associated osteosarcomas developed
local recurrences, which were characterized by bulky,
unresectable disease in all but 1 (Patient 17). Two
FIGURE 1. Osteoblastic osteosarcoma in a patient with primary mandibu-
lar osteosarcoma (Case 9). (A) Computed tomography scan shows a well-cir-
cumscribed, heavily mineralized tumor involving the body of the mandible,
which was resected with negative margins. (B) Histologically, it had exten-
sive malignant osteoid production. Osteoblastic osteosarcoma was the most
frequent histologic type of primary craniofacial osteosarcoma (9 of 15
patients) in this study.
FIGURE 2. Chondroblastic osteosarcoma in a patient with primary mandi-
bular osteosarcoma (Case 7). Chondroblastic osteosarcoma was a frequent
variant in primary craniofacial osteosarcoma (5 of 15 patients) in this study,
exemplified by this low-grade tumor that produced both chondroid and
osteoid matrix.
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patients (Patients 18 and 19) had been treated for
bilateral retinoblastomas in childhood and developed
radiation-associated osteosarcomas 18 and 20 years
afterwards. Both had unresectable tumors and 1 died
of disease that included metastasis to the brain. At
the time of last follow-up, 3 (50%) of the radiation-
associated osteosarcoma patients had died of disease
and 2 were alive with unresectable disease at 12 and
84 months. One was alive with no evidence of dis-
ease at 48 months.
FIGURE 5. Immunohistochemical ezrin staining in craniofacial radiation-asso-
ciated osteosarcoma. Cytoplasmic and membranous staining for the membrane
cytoskeletal organizer protein ezrin was more common in craniofacial radiation-
associated than primary craniofacial osteosarcoma (83% vs. 40%).
FIGURE 3. Fibroblastic osteosarcoma in a patient with a radiation-asso-
ciated maxillary osteosarcoma (Case 19). (A) Computed tomography scan
shows a poorly circumscribed and destructive tumor involving the maxilla
and paranasal sinuses in a patient with a history of retinoblastoma. The
tumor was unresectable. (B) Histologically it was a high-grade, pleomorphic,
spindle-cell sarcoma that had only focal malignant osteoid production. Fibro-
blastic osteosarcoma was a frequent finding in craniofacial radiation-asso-
ciated osteosarcoma (3 of 6 patients) in this study. In contrast, only 1
primary craniofacial osteosarcoma was fibroblastic.
FIGURE 4. Immunohistochemical p53 staining in craniofacial radiation-
associated osteosarcoma. Strong nuclear staining such as this was more fre-
quent in radiation-associated than in primary craniofacial osteosarcoma
(33% vs. 13%, respectively). In addition, mutations of TP53 tumor suppres-
sor gene were also more frequent in craniofacial radiation-associated osteo-
sarcoma (33% vs. 8%).
TABLE 2
Immunohistochemical and TP53 Mutational Analysis of Prognostic
Markers Comparing Primary and Radiation-Associated Craniofacial
Osteosarcoma
p53, % TP53 mutation, % Ezrin, % >50% MIB-1, %
Primary OS (n ¼ 15) 13 8 40 0
RAOS (n ¼ 6) 33 33 83 67
OS indicates osteosarcoma; RAOS, radiation-associated osteosarcoma.
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Among the primary craniofacial osteosarcoma
patients, 5 (33%) developed local recurrences and 1
had metastatic disease to a regional lymph node. At
last follow-up, 12 (80%) were alive with no evidence
of disease, 2 (13%) had died of disease, and 1 was
alive with disease at 14 months. Comparing low- and
high-grade primary craniofacial osteosarcomas, pa-
tients with low-grade tumors had a better prognosis.
Of the 8 patients with low-grade tumors, all were
alive with no evidence of disease. In contrast, of the
7 patients with high-grade tumors, 2 had died of dis-
ease, 1 was alive with persistent disease, and four
were alive without disease, including the 1 patient
who had a lymph node metastasis.
DISCUSSION
Although uncommon, radiation-associated sarcoma
of bone is a well-recognized entity associated with
poor prognosis. In a review of 78 cases by Weatherby
et al.,10 osteosarcoma was the most frequent histolo-
gic type (49%), followed by fibrosarcoma (41%). Six-
teen (21%) of these cases occurred in the craniofacial
bones: 7 in the maxilla, 4 in the mandible, and 5 in
the cranium. Only 4 of the 16 patients with craniofa-
cial radiation-associated osteosarcoma in that study
were symptom-free survivors after 5 years, in addi-
tion to another patient who had a recurrence at
8 years and ultimately died of metastatic disease.
Other authors have reported similar findings
regarding craniofacial radiation-associated osteosar-
coma. Arlen et al.9 reported 7 (14%) head and neck
tumors among 50 radiation-induced osteosarcomas.
All but 1 developed local recurrences and all 7
patients died of disease within 3 years. In another
study, Bennett et al.8 reported 22 cases of osteosar-
coma of jaws including 4 with radiation-associated
osteosarcoma. All 4 of these patients developed local
recurrences and 3 died of disease within 2 years of
diagnosis. In contrast, only half the patients with pri-
mary osteosarcoma developed recurrence.
Not all studies have demonstrated a worse prog-
nosis for craniofacial radiation-associated osteosar-
coma.3,16,17 For example, Oda et al.17 identified 2
cases of radiation-associated head and neck osteo-
sarcoma among a series of 13 cases, and both
patients were alive with no evidence of disease at 84
and 180 months. Ha et al.,16 in a series of 27 head
and neck osteosarcoma, found no detectable effect
of prior radiation exposure on survival.
In this study we found craniofacial radiation-
associated osteosarcoma to have a poor prognosis
compared with primary craniofacial osteosarcoma.
All 6 patients with radiation-associated osteosarcoma
in our study developed local recurrences with bulky,
unresectable disease in all but 1. Three died, 2 had
uncontrolled, locally aggressive tumors, and only 1
was alive with no evidence of disease. In contrast,
80% of the patients with primary craniofacial osteo-
sarcoma were alive with no evidence of disease, and
only 2 (13%) had died of disease. These survival data
were not affected by different treatment regimens
between the 2 groups, as similar rates of chemother-
apy treatment were identified among the patients
with high-grade tumors.
Similar to findings in prior studies,3,4,8 we found
low rates of metastases compared with patients with
conventional osteosarcoma of the long bones. Over-
all, only 2 patients had documented metastatic dis-
ease, including 1 primary and 1 radiation-associated
tumor, both of which were high grade. Therefore,
similar rates of metastases were identified among
high-grade tumors in both groups (14% vs. 20% in
primary and radiation-associated craniofacial osteo-
sarcoma, respectively).
All craniofacial radiation-associated osteosarco-
mas in this study were high grade, compared with
only 47% of the primary osteosarcomas. Although
results have varied, a number of studies correlate
high-grade histology with worse prognosis.16,23 For
example, high-grade tumors and positive surgical
margins were the only features impacting survival in
a study of 27 head and neck osteosarcomas by Ha
et al.16 Similarly, Slootweg and Muller23 identified
older age and high-grade histology as the only fea-
tures affecting prognosis in a study of 18 osteosarco-
mas of the jaws. Our data show similar findings as
these authors. Clearly the radiation-associated cra-
niofacial osteosarcomas, which were all high grade,
did worse. However, when we separately analyzed
our cases of primary craniofacial osteosarcoma by
grade, the high-grade tumors similarly did worse
than the low-grade tumors. Thus, the preponderance
of high-grade tumors among radiation-associated
osteosarcomas appears to be an important prognos-
tic variable.
Another histologic feature that differed between
the 2 groups was a disproportionately higher percen-
TABLE 3
Immunohistochemical and TP53 Mutational Analysis of Prognostic
Markers Comparing Low- and High-Grade Extremity Osteosarcoma
p53, % TP53 mutation, % Ezrin, % >50% MIB-1, %
Low-grade OS (n ¼ 7) 0 14 57 0
High grade OS (n ¼ 22) 18 21 72 50
OS indicates osteosarcoma.
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tage of fibroblastic osteosarcomas in the radiation-
associated osteosarcoma group. Other studies have
similarly identified a higher rate of fibroblastic osteo-
sarcoma in radiation-associated osteosarcoma.14,24
For example, Huvos et al.24 in a series of 66 postra-
diation osteosarcomas from all sites found fibroblas-
tic osteosarcoma to be the most frequent histologic
type, accounting for 49% of the tumors. Similarly,
Shah et al.14 found high numbers of craniofacial
osteosarcomas with fibroblastic histology in retino-
blastoma patients who developed postradiation
osteosarcomas. These findings are intriguing because
in the long bones fibroblastic osteosarcoma has been
shown to behave more aggressively.25
p53 protein participates in regulation of the early
G1 phase of the cell cycle and participates in apopto-
sis. TP53 gene mutations, which are commonly
accompanied by immunohistochemical p53 overex-
pression,26 appear to play an important role in the
pathogenesis of postradiation sarcoma.27 Junior
et al.2 identified p53 overexpression in 52% of tumors
in a series of 25 head and neck osteosarcoma, with
most tumors (32%) reported as strongly positive
(>50% of nuclei with positive staining). Although
they did not correlate p53 staining with radiation his-
tory or prognosis, they did find a correlation with
grade in that 73% of high-grade tumors were positive
compared with only 36% of low- and intermediate-
grade tumors. In another study, Olivera et al.28 found
47.5% of 17 of jaw osteosarcomas to overexpress p53,
but also could not correlate staining with prognosis.
Lopes et al.29 identified overexpression in 88% of
osteosarcomas of the jaws in their study of 9 cases,
including 5 that were strongly positive.
In our study, p53 was overexpressed in 24% of
cases, evidenced by strong nuclear staining in >50%
of cells. Radiation-associated osteosarcomas more
often overexpressed p53 than primary tumors (33%
vs. 13%), and more often had detectable mutations
of the TP53 gene (33% vs. 7%). Although most stu-
dies have shown p53 expression not to be prognosti-
cally useful, our data support a role for p53 in the
pathogenesis of craniofacial radiation-associated
osteosarcoma. However, further investigation with
larger patient groups and molecular analyses is
warranted.
Ezrin is a membrane-cytoskeleton linker protein
belonging to the Band 4.1 protein superfamily and is
the best-characterized ezrin-radixin-moesin pro-
tein.30 Ezrin-radixin-moesin proteins are cytosolic
proteins that when phosphorylated localize to the
cell membrane where they link F-actin to the cell
membrane.30 In essence, this allows the cell to inter-
act with its microenvironment while facilitating
intracellular signal transduction. These processes are
thought to be responsible for its role in the develop-
ment of metastases.30 In fact, immunohistochemical
staining for ezrin in metastatic osteosarcoma has
been shown to be of membranous type, whereas pri-
mary and recurrent tumors demonstrate both mem-
branous and cytoplasmic staining.31 Ezrin expression
has been reported in osteosarcomas as well as in
other malignancies.31 However, no prior studies on
its expression or association with outcome in radia-
tion-associated or primary craniofacial osteosarcoma
have been reported.
The craniofacial radiation-associated osteosarco-
mas in our study more often expressed ezrin (cyto-
plasmic and/or membranous pattern) compared
with the primary tumors (83% vs. 40%). Furthermore,
ezrin expression appeared to be independent of
grade. The expression pattern demonstrated in this
study indicates that ezrin positivity may be a prog-
nostic marker for craniofacial osteosarcoma and may
shed light on the clinical and biologic differences
between primary and radiation-associated craniofa-
cial osteosarcoma.
A number of proteins expressed in actively pro-
liferating cells have been identified. Among these, Ki-
67 is commonly used and its prognostic value has
been described in many tumor types. Unfortunately,
little data exist on its use in osteosarcoma,32 espe-
cially craniofacial and radiation-associated osteosar-
coma. Park and Park32 identified weak staining for
Ki-67 in 64% of 67 osteosarcomas from all sites. In a
study of 25 head and neck osteosarcomas by Junior
et al.,2 88% were positive for Ki-67, including 48%
that were strongly positive. However, they were
unable to correlate Ki-67 positivity with prognosis,
and no evaluation as to correlation with grade or
association with radiation exposure was made. In our
series, 4 of 6 of the radiation-associated osteosarco-
mas showed very high levels of Ki-67 expression
(>50% nuclear staining) as compared with none with
this degree of staining in the primary osteosarcoma
group. In the primary osteosarcomas, the high-grade
tumors tended to have higher proliferation rates, but
did not approach the levels seen in the radiation-
associated osteosarcoma.
Retinoblastoma results from deletion of the
13q14 region of the RB tumor suppressor gene and,
although survival for this tumor is excellent, a well-
known complication is the development of a second
nonocular malignant tumor occurring predominately
in patients with bilateral retinoblastomas harboring
germline RB mutations.33 Secondary malignant tu-
mors in these patients are believed in large part to
be radiation-induced, and the incidence has been
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correlated with radiation dose.13 In a review of 688
retinoblastoma patients who survived after radiation
therapy, 13% developed second tumors, 70% of
which occurred in the radiation field.33 The most
common histology was osteosarcoma (39.4%). Radia-
tion-associated craniofacial osteosarcoma in these
patients has a poor prognosis.14
Decreased immunohistochemical pRB staining
correlates with decreased expression of the RB gene
product. Radiation therapy has been suggested to
induce RB mutations as a possible mechanism parti-
cipating in radiation-associated osteosarcoma.34 In
our study, no difference was found in pRB expression
between primary and radiation-associated osteosar-
coma (56% vs. 50%), providing little evidence for an
increased rate of RB gene deletions in patients
exposed to radiation.
In summary, our findings demonstrate important
biologic and clinicopathologic differences between pri-
mary and radiation-associated craniofacial osteosar-
coma, indicating that these are distinct clinical entities
with different prognoses, which may benefit from dif-
ferent therapeutic approaches. Survival was worse in
patients with radiation-associated osteosarcoma, with
most deaths resulting from unresectable, locally aggres-
sive tumors. In addition, all were high grade and half
were fibroblastic, an otherwise uncommon morphol-
ogy in craniofacial osteosarcoma. Craniofacial radia-
tion-associated osteosarcomas are more likely to be
associated with adverse prognostic markers such as
p53 overexpression, TP53 mutation, ezrin expression,
and high proliferative activity. These differences paral-
lel those between high- and low-grade extremity
osteosarcomas, suggesting histologic grade to be an
important variable responsible for the poor outcome
in craniofacial radiation-associated osteosarcoma.
Although confirmation of these findings with a larger
cohort of patients is warranted, these results suggest
that craniofacial radiation-associated osteosarcoma
has distinctive biologic and clinicopathologic charac-
teristics, knowledge of which may assist in determin-
ing prognosis and guiding clinical management.
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